JPM vs MCB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MCB presents a stark dichotomy between extreme valuation attractiveness and deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the stock trades significantly below its Graham Number ($115.79) and Intrinsic Value ($238.66), the low F-Score suggests poor quality of earnings or declining operational efficiency. Explosive YoY earnings growth (101.4%) is offset by bearish insider sentiment and a very weak technical trend (10/100). The company's reliance on Banking-as-a-Service (BaaS) introduces regulatory risks that may be pricing into the current discount.
Compare Another Pair
Related Comparisons
JPM vs MCB: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Metropolitan Bank Holding Corp. (MCB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.